In short: BUY. ER 13.90%; fwd PE 30.5 vs 59.6 (48.8% under); RDCF 24.8% vs 15.0% (−9.8pp). YTD +8.8%.
In short: Fifth-best performer at +38.6%. Rated BUY on the 23 August sheet at a 30.5 forward PE against a 59.6 five-year average — but with the worst reverse-DCF gap on that whole Buy list (25.7% growth required against 15.0% expected). The rally makes that gap wider, and the issue does not revisit it.
In short: BUY. Fwd PE 30.5 against a 59.6 five-year average (48.8% under) and ER 13.80% on 15.0% growth — but the reverse DCF demands 25.7% growth against 15.0% expected, a −10.7pp gap, the worst on the entire Buy list. YTD +15.4%; five-year CAGR −14%, ten-year 24%.
In short: BUY. FV SEK 538.5 vs 262.8 = 51.2% under; ER 14.2%; fwd PE 30.5 against 59.6 (48.8% under) — the multiple has risen since June as estimates moved; RDCF 12.0% vs 15.0% expected, now positive where June's read −0.7pp. YTD −22.7%.
In short: BUY — and the forward-PE screen's spotlight. "A Swedish safety technology company that develops patented brain protection systems for helmets… this market leader is trading at its cheapest valuation level ever," and "expected to triple its earnings in the next few years." FV SEK 622.9 vs 237.2 = 61.9% under; fwd PE 23.8 against a 59.6 five-year average (60.1% under); RDCF 15.7% required vs 15.0% expected — the one caveat: the price still demands the tripling.
Mips is a small Swedish company that licenses a patented safety system built into helmets — a low-friction layer that lets the shell rotate slightly on impact, reducing the twisting force transmitted to the brain. It does not make helmets; it charges the manufacturers a fee per helmet, which is a very light way to make money.
The shares now trade at about 24 times expected profits against a five-year average of 60 — the cheapest the company has ever been — while the expectation is that profits roughly triple over the next few years. The single caution is in the third model: at this price the market is already assuming about 15% growth, so this is cheap relative to its own history rather than cheap in absolute terms. The tripling has to happen.
In short: Eighth-worst watchlist performer at −32.1% year to date, on a 16.2% ten-year CAGR. Not rated Buy this month.
Nothing matches this filter.
Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.